Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma

doi:10.1084/jem.146.3.720

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by DeLeo, A. B.
	Articles by Old, L. J.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by DeLeo, A. B.
	Articles by Old, L. J.


Social Bookmarking

	What's this?

ARTICLES

Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma

AB DeLeo, H Shiku, T Takahashi, M John and LJ Old

As background for a serological definition of the unique antigens of chemically induced sarcomas, we have typed a series of fibroblast and sarcoma cell lines of BALB/c and C57BL/6 origin by cytoxicity and absorption tests for murine leukemia virus (MuLV)-related cell surface antigens and known alloantigens. 7 of the 17 cultured lines expressed the range of cell surface antigens associated with MuLV (GIX, GCSA, gp70, p30), and this was invariably associated with MuLV production. In nonproducer lines of C57BL/6 (but not BALB/c) origin, a MuLV-gp70-like molecule was found on the surface of fibroblasts and sarcoma cells. The alloantigenic phenotype of these MuLV+ and MuLV- cell lines was H-2D+, H-2K+, Thy-1.2+ or -, PC.1+ or -, Lyt-1.2-, Lyt-2.2-, Ia.7-, and TL.2-. A unique antigen was defined on the BALB/c ascites sarcoma Meth A with antisera prepared in BALB/c or (BALB/c X C57BL/6)F1 mice. Tissue culture lines derived from this tumor were MuLV-, which facilitated serological study of the antigen. Absorption analysis indicated that the antigen was restricted to Meth A; it could not be detected in normal or fetal BALB/c tissue MuLV+ or MuLV- fibroblast lines, 12 syngeneic or allogeneic sarcomas, or normal lymphoid cells from 13 different inbred mouse strains.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Nishikawa, H., Kato, T., Tawara, I., Ikeda, H., Kuribayashi, K., Allen, P. M., Schreiber, R. D., Old, L. J., Shiku, H. (2005). IFN-{gamma} Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response. J. Immunol. 175: 4433-4440 [Abstract] [Full Text]
Liu, K., Caldwell, S. A., Abrams, S. I. (2005). Immune Selection and Emergence of Aggressive Tumor Variants as Negative Consequences of Fas-Mediated Cytotoxicity and Altered IFN-{gamma}-Regulated Gene Expression. Cancer Res. 65: 4376-4388 [Abstract] [Full Text]
O'Mara, L. A., Norian, L. A., Kreamalmeyer, D., White, J. M., Allen, P. M. (2005). T Cell-Mediated Delay of Spontaneous Mammary Tumor Onset: Increased Efficacy with In Vivo versus In Vitro Activation. J. Immunol. 174: 4662-4669 [Abstract] [Full Text]
Liu, K., Caldwell, S. A., Abrams, S. I. (2005). Cooperative Disengagement of Fas and Intercellular Adhesion Molecule-1 Function in Neoplastic Cells Confers Enhanced Colonization Efficiency. Cancer Res. 65: 1045-1054 [Abstract] [Full Text]
Daftarian, P., Song, G.-Y., Ali, S., Faynsod, M., Longmate, J., Diamond, D. J., Ellenhorn, J. D. I. (2004). Two Distinct Pathways of Immuno-Modulation Improve Potency of p53 Immunization in Rejecting Established Tumors. Cancer Res. 64: 5407-5414 [Abstract] [Full Text]
Norian, L. A., Allen, P. M. (2004). No Intrinsic Deficiencies in CD8+ T Cell-Mediated Antitumor Immunity with Aging. J. Immunol. 173: 835-844 [Abstract] [Full Text]
Hanson, H. L., Kang, S. S., Norian, L. A., Matsui, K., O'Mara, L. A., Allen, P. M. (2004). CD4-Directed Peptide Vaccination Augments an Antitumor Response, but Efficacy Is Limited by the Number of CD8+ T Cell Precursors. J. Immunol. 172: 4215-4224 [Abstract] [Full Text]
O'Mara, L. A., Allen, P. M. (2004). Pulmonary Tumors Inefficiently Prime Tumor-Specific T Cells. J. Immunol. 172: 310-317 [Abstract] [Full Text]
Nishikawa, H., Kato, T., Tanida, K., Hiasa, A., Tawara, I., Ikeda, H., Ikarashi, Y., Wakasugi, H., Kronenberg, M., Nakayama, T., Taniguchi, M., Kuribayashi, K., Old, L. J., Shiku, H. (2003). CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl. Acad. Sci. USA 100: 10902-10906 [Abstract] [Full Text]
van Ojik, H. H., Bevaart, L., Dahle, C. E., Bakker, A., Jansen, M. J. H., van Vugt, M. J., van de Winkel, J. G. J., Weiner, G. J. (2003). CpG-A and B Oligodeoxynucleotides Enhance the Efficacy of Antibody Therapy by Activating Different Effector Cell Populations. Cancer Res. 63: 5595-5600 [Abstract] [Full Text]
Caldwell, S. A., Ryan, M. H., McDuffie, E., Abrams, S. I. (2003). The Fas/Fas Ligand Pathway Is Important for Optimal Tumor Regression in a Mouse Model of CTL Adoptive Immunotherapy of Experimental CMS4 Lung Metastases. J. Immunol. 171: 2402-2412 [Abstract] [Full Text]
Matsui, K., O'Mara, L. A., Allen, P. M. (2003). Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. Int Immunol 15: 797-805 [Abstract] [Full Text]
Liu, K., Abrams, S. I. (2003). Alterations in Fas Expression Are Characteristic of, But Not Solely Responsible for, Enhanced Metastatic Competence. J. Immunol. 170: 5973-5980 [Abstract] [Full Text]
Uenaka, A., Hirano, Y., Hata, H., Win, S., Aji, T., Tanaka, M., Ono, T., Skipper, J. C. A., Shimizu, K., Nakayama, E. (2003). Cryptic CTL Epitope on a Murine Sarcoma Meth A Generated by Exon Extension as a Novel Mechanism. J. Immunol. 170: 4862-4868 [Abstract] [Full Text]
Espenschied, J., Lamont, J., Longmate, J., Pendas, S., Wang, Z., Diamond, D. J., Ellenhorn, J. D. I. (2003). CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model. J. Immunol. 170: 3401-3407 [Abstract] [Full Text]
Nishikawa, H., Tanida, K., Ikeda, H., Sakakura, M., Miyahara, Y., Aota, T., Mukai, K., Watanabe, M., Kuribayashi, K., Old, L. J., Shiku, H. (2001). Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc. Natl. Acad. Sci. USA 10.1073/pnas.251547298v1 [Abstract] [Full Text]
Ryan, M. H., Bristol, J. A., McDuffie, E., Abrams, S. I. (2001). Regression of Extensive Pulmonary Metastases in Mice by Adoptive Transfer of Antigen-Specific CD8+ CTL Reactive Against Tumor Cells Expressing a Naturally Occurring Rejection Epitope. J. Immunol. 167: 4286-4292 [Abstract] [Full Text]
Galanos, C., Gumenscheimer, M., Muhlradt, P.F., Jirillo, E., Freudenberg, M.A. (2000). MALP-2, a Mycoplasma lipopeptide with classical endotoxic properties: end of an era of LPS monopoly?. Innate Immunity 6: 471-476 [Abstract]
Salvadori, S., Martinelli, G., Zier, K. (2000). Resection of Solid Tumors Reverses T Cell Defects and Restores Protective Immunity. J. Immunol. 164: 2214-2220 [Abstract] [Full Text]
Sturmhoefel, K., Lee, K., Gray, G. S., Thomas, J., Zollner, R., O'Toole, M., Swiniarski, H., Dorner, A., Wolf, S. F. (1999). Potent Activity of Soluble B7-IgG Fusion Proteins in Therapy of Established Tumors and as Vaccine Adjuvant. Cancer Res. 59: 4964-4972 [Abstract] [Full Text]
Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., Nakayama, E. (1999). Tumor Rejection by in Vivo Administration of Anti-CD25 (Interleukin-2 Receptor {{alpha}}) Monoclonal Antibody. Cancer Res. 59: 3128-3133 [Abstract] [Full Text]
Matsuo, M., Wada, H., Honda, S., Tawara, I., Uenaka, A., Kanematsu, T., Nakayama, E. (1999). Expression of Multiple Unique Rejection Antigens on Murine Leukemia BALB/c RL[IMAGE]1 and the Role of Dominant Akt Antigen for Tumor Escape. J. Immunol. 162: 6420-6425 [Abstract] [Full Text]
Rohrer, J. W., Barsoum, A. L., Dyess, D. L., Tucker, J. A., Coggin, J. H. Jr. (1999). Human Breast Carcinoma Patients Develop Clonable Oncofetal Antigen-Specific Effector and Regulatory T Lymphocytes. J. Immunol. 162: 6880-6892 [Abstract] [Full Text]
Janus, F., Albrechtsen, N., Knippschild, U., Wiesmuller, L., Grosse, F., Deppert, W. (1999). Different Regulation of the p53 Core Domain Activities 3'-to-5' Exonuclease and Sequence-Specific DNA Binding. Mol. Cell. Biol. 19: 2155-2168 [Abstract] [Full Text]
Dudenhöffer, C., Rohaly, G., Will, K., Deppert, W., Wiesmüller, L. (1998). Specific Mismatch Recognition in Heteroduplex Intermediates by p53 Suggests a Role in Fidelity Control of Homologous Recombination. Mol. Cell. Biol. 18: 5332-5342 [Abstract] [Full Text]
Ikeda, H., Ohta, N., Furukawa, K., Miyazaki, H., Wang, L., Furukawa, K., Kuribayashi, K., Old, L. J., Shiku, H. (1997). Mutated mitogen-activated protein kinase: A tumor rejection antigen of mouse�sarcoma. Proc. Natl. Acad. Sci. USA 94: 6375-6379 [Abstract] [Full Text]
VedBrat, S. S., Hammerling, U., Hardy, W. D. Jr., Borenfreund, E., Prensky, W. (1980). Monoclonal Antibodies: Detection of Transformation-related Antigens. Cold Spring Harb Symp Quant Biol 44: 715-720 [Abstract]
Nishikawa, H., Tanida, K., Ikeda, H., Sakakura, M., Miyahara, Y., Aota, T., Mukai, K., Watanabe, M., Kuribayashi, K., Old, L. J., Shiku, H. (2001). Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc. Natl. Acad. Sci. USA 98: 14571-14576 [Abstract] [Full Text]